Terms: = Ovarian cancer AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025
24 results:
1. Small Molecule Antagonists of the DNA Repair ERCC1/xpa Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract] [Full Text] [Related]
2. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of tumor suppressor promoter methylation in healthy individuals.
Poduval DB; Ognedal E; Sichmanova Z; Valen E; Iversen GT; Minsaas L; Lønning PE; Knappskog S
Clin Epigenetics; 2020 Aug; 12(1):131. PubMed ID: 32859265
[TBL] [Abstract] [Full Text] [Related]
4. The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.
Zhao Z; Zhang A; Zhao Y; Xiang J; Yu D; Liang Z; Xu C; Zhang Q; Li J; Duan P
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29669843
[TBL] [Abstract] [Full Text] [Related]
5. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
[TBL] [Abstract] [Full Text] [Related]
6. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract] [Full Text] [Related]
7. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.
Ganzinelli M; Mariani P; Cattaneo D; Fossati R; Fruscio R; Corso S; Ricci F; Broggini M; Damia G
Eur J Cancer; 2011 May; 47(7):1086-94. PubMed ID: 21216588
[TBL] [Abstract] [Full Text] [Related]
8. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract] [Full Text] [Related]
10. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract] [Full Text] [Related]
11. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
Stevens EV; Raffeld M; Espina V; Kristensen GB; Trope' CG; Kohn EC; Davidson B
Cancer; 2005 Jun; 103(11):2313-9. PubMed ID: 15844177
[TBL] [Abstract] [Full Text] [Related]
12. Reduced levels of xpa, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
Welsh C; Day R; McGurk C; Masters JR; Wood RD; Köberle B
Int J Cancer; 2004 Jun; 110(3):352-61. PubMed ID: 15095299
[TBL] [Abstract] [Full Text] [Related]
13. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract] [Full Text] [Related]
14. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors.
Takebayashi Y; Nakayama K; Kanzaki A; Miyashita H; Ogura O; Mori S; Mutoh M; Miyazaki K; Fukumoto M; Pommier Y
Cancer Lett; 2001 Dec; 174(2):115-25. PubMed ID: 11689286
[TBL] [Abstract] [Full Text] [Related]
15. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract] [Full Text] [Related]
16. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Dabholkar M; Thornton K; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
Biochem Pharmacol; 2000 Dec; 60(11):1611-9. PubMed ID: 11077043
[TBL] [Abstract] [Full Text] [Related]
17. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E; Dabholkar M; Thornton K; Thompson C; Yu JJ; Bostick-Bruton F
Oncol Rep; 2000; 7(5):1123-8. PubMed ID: 10948350
[TBL] [Abstract] [Full Text] [Related]
18. Computer based analyses of the 5'-flanking regions of selected genes involved in the nucleotide excision repair complex.
Zhong X; Thornton K; Reed E
Int J Oncol; 2000 Aug; 17(2):375-80. PubMed ID: 10891549
[TBL] [Abstract] [Full Text] [Related]
19. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
[TBL] [Abstract] [Full Text] [Related]
20. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.
Damia G; Guidi G; D'Incalci M
Eur J Cancer; 1998 Oct; 34(11):1783-8. PubMed ID: 9893669
[TBL] [Abstract] [Full Text] [Related]
[Next]
